enzyme of the mevalonate‐independent pathway of the isoprenoid biosynthesis. Using fosmidomycin as a specific inhibitor of Dxr, this enzyme was previously validated as target for the treatment of malaria and bacterial infections. The replacement of the formyl residue of fosmidomycin by spacious acyl residues yielded inhibitors active in the micromolar range. As predicted by flexible docking, evidence was
1 - 脱氧 - D -
木酮糖 - 5 -
磷酸还原异构酶 (Dxr) 代表类
异戊二烯生物合成的非甲羟
戊酸途径的必需酶。使用 fosmidomycin 作为 Dxr 的特异性
抑制剂,这种酶以前被验证为治疗疟疾和细菌感染的靶点。fosmidomycin 的甲酰基残基被宽敞的酰基残基取代产生了在微摩尔范围内有活性的
抑制剂。正如柔性对接所预测的那样,获得了在酰基残基中适当放置的羰基与位于酶的柔性催化环中的 Met214 的主链 NH 之间形成氢键的证据。